chr13-48045719-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_018283.4(NUDT15):c.415C>T(p.Arg139Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0117 in 1,612,064 control chromosomes in the GnomAD database, including 632 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).
Frequency
Genomes: 𝑓 0.013 ( 67 hom., cov: 32)
Exomes 𝑓: 0.012 ( 565 hom. )
Consequence
NUDT15
NM_018283.4 missense
NM_018283.4 missense
Scores
1
17
Clinical Significance
Conservation
PhyloP100: 4.41
Genes affected
NUDT15 (HGNC:23063): (nudix hydrolase 15) This gene encodes an enzyme that belongs to the Nudix hydrolase superfamily. Members of this superfamily catalyze the hydrolysis of nucleoside diphosphates, including substrates like 8-oxo-dGTP, which are a result of oxidative damage, and can induce base mispairing during DNA replication, causing transversions. The encoded enzyme is a negative regulator of thiopurine activation and toxicity. Mutations in this gene result in poor metabolism of thiopurines, and are associated with thiopurine-induced early leukopenia. Multiple pseudogenes of this gene have been identified. [provided by RefSeq, Apr 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -12 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0037097335).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.0941 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NUDT15 | NM_018283.4 | c.415C>T | p.Arg139Cys | missense_variant | 3/3 | ENST00000258662.3 | NP_060753.1 | |
NUDT15 | NR_136687.2 | n.436C>T | non_coding_transcript_exon_variant | 3/5 | ||||
NUDT15 | NR_136688.2 | n.436C>T | non_coding_transcript_exon_variant | 3/5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NUDT15 | ENST00000258662.3 | c.415C>T | p.Arg139Cys | missense_variant | 3/3 | 1 | NM_018283.4 | ENSP00000258662.1 |
Frequencies
GnomAD3 genomes AF: 0.0126 AC: 1908AN: 152016Hom.: 66 Cov.: 32
GnomAD3 genomes
AF:
AC:
1908
AN:
152016
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0282 AC: 7054AN: 249720Hom.: 276 AF XY: 0.0281 AC XY: 3798AN XY: 135108
GnomAD3 exomes
AF:
AC:
7054
AN:
249720
Hom.:
AF XY:
AC XY:
3798
AN XY:
135108
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0117 AC: 17014AN: 1459930Hom.: 565 Cov.: 30 AF XY: 0.0129 AC XY: 9382AN XY: 726348
GnomAD4 exome
AF:
AC:
17014
AN:
1459930
Hom.:
Cov.:
30
AF XY:
AC XY:
9382
AN XY:
726348
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0126 AC: 1912AN: 152134Hom.: 67 Cov.: 32 AF XY: 0.0146 AC XY: 1086AN XY: 74362
GnomAD4 genome
AF:
AC:
1912
AN:
152134
Hom.:
Cov.:
32
AF XY:
AC XY:
1086
AN XY:
74362
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
9
ALSPAC
AF:
AC:
12
ESP6500AA
AF:
AC:
4
ESP6500EA
AF:
AC:
21
ExAC
AF:
AC:
3377
Asia WGS
AF:
AC:
299
AN:
3478
ClinVar
Significance: drug response
Submissions summary: Benign:1Other:3
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
NUDT15-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 22, 2021 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Thiopurines, poor metabolism of, 2 Other:1
drug response, no assertion criteria provided | literature only | OMIM | Oct 25, 2016 | - - |
azathioprine response - Toxicity Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. Drug-variant association: Toxicity |
mercaptopurine response - Dosage Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. Drug-variant association: Dosage |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
T
Sift4G
Benign
T
Polyphen
P
Vest4
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at